Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

NCT06302569 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Bellini Carcinoma
Collecting Duct Carcinoma
Renal Medullary Carcinoma

Interventions

DRUG: Pembrolizumab + Enfortumab Vedotin

Sponsor

Giuseppe Procopio